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1. ABSTRACT 
 
The integrity of mitochondrial function is 
fundamental to cell life. The cell demands for mitochondria 
and their complex integration into cell biology, extends far 
beyond the provision of ATP. It follows that disturbances 
of mitochondrial function lead to disruption of cell 
function, expressed as disease or even death. Mitochondria 
are major producers of free radical species and also
 
 
 
 
 
possibly of nitric oxide, and are, at the same time, major targets 
for oxidative damage. In this review we consider recent 
developments in our knowledge of how the mitochondrial 
production of reactive oxygen species (ROS) plays a critical 
role in several major human pathologies. We will also consider 
recent advances in our understanding of the molecular 
mechanisms involved in mitochondrial ROS detoxification. 
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Figure 1. Main mitochondrial ROS detoxification 
enzymes. 
 
2. INTRODUCTION  
 
Mitochondria have been considered the 
powerhouse of the living cell. Their main function is the 
generation of energy in the form of the molecule ATP, a 
process that takes place through oxidative phosphorylation 
(1, 2). But, mitochondria are not just providers of energy, 
they are involved in many other aspects of cell physiology, 
the best known being calcium signaling, and programmed 
cell death (apoptosis) (3). 
 
Generation of reactive oxygen species (ROS) in 
mitochondria is a consequence of the action of the electron 
transfer associated with oxidative phosphorylation that 
generates unpaired electrons. It has been estimated that 1-
2% of the electrons that travel along the electron transfer 
(ETC) react with molecular oxygen (O2) to produce the 
anion superoxide (O2-) a highly reactive free radical 
species. The superoxide anion-radical is readily converted 
to ROS,  such as hydrogen peroxide (H2O2) and hydroxyl 
radicals (HO.). There is no question that mitochondria are 
the major source of oxygen free radical generation in most 
cell types, except perhaps for macrophages, which express 
an NADPH oxidase that generates massive amounts of O2- 
after stimulation. 
 
The chemical species called ROS are able to 
cause lipid peroxidation and damage to cell membranes, 
proteins and DNA, so that mitochondria represent not only 
a major source of ROS generation, but also a major target 
of ROS induced damage. The high rate of mitochondrial 
DNA (mtDNA) mutation (10-fold higher than in the 
nuclear DNA (nDNA)) will eventually result in the 
accumulation of mutations in mitochondrial proteins. 
Defective proteins will in turn exacerbate mitochondrial 
dysfunction, increase production of ROS, and reduce 
mitochondrial energy production. 
 
Mitochondria are equipped with an 
armamentarium of antioxidant defenses (Figure 1) and 
contain a high concentration of glutathione, mainly reduced 
glutathione (GSH) fundamental to cell survival. Although 
still not thoroughly investigated, important members of this 
system are Mn superoxide dismutase (Mn-SOD), 
peroxiredoxins III and V (Prx3, Prx5), mitochondrial 
thioredoxin (Trx2) and, mitochondrial thioredoxin 
reductase (TrxR2), mitochondrial glutaredoxin (Grx2a), 
mitochondrial glutaredoxin reductase (mtGrxR), glutathion 
peroxidase 4 (GPX4), uncoupling protein 2 (UCP-2), and a 
specific set of heat shock proteins. 
 
In general, the leak of electrons from the electron 
transfer chain seems to be increased by an increase in 
mitochondrial potential and decreased with mitochondrial 
depolarization. Provided that mitochondrial activity can 
vary greatly, as well as electron transfer efficiency as 
phosphorylation coupling, mitochondrial ROS production 
can change rapidly in various physiological and 
pathological conditions. Therefore the oxidative protection 
system must be under tight regulatory control. Several 
transcription factors, and biomolecules like nitric oxide 
(NO) have been proposed to modulate the expression of at 
least one member of the system, but until recently a 
coordinated regulation had not been described. Peroxisome 
proliferator activated receptor gamma coactivator 1 alpha 
(PGC-1alpha), a transcriptional coactivator well known as a 
key regulator of mitochondrial biogenesis and lipid 
catabolism, has been shown to be a master regulator of the 
mitochondrial oxidative stress protection system in 
endothelial cells, a role that is likely to play in other cells 
systems, particularly those with high metabolic rates where 
PGC-1alpha has a crucial role in the control of energy 
metabolism.  
 
Mutations in mitochondrial genes have been 
shown to cause many different genetic diseases (i.e. LHON 
dystony, Leigh´s disease) (4). Phenotypes of mitochondrial 
diseases can be both diverse and overlapping, that is, the 
same mutation can produce quite different phenotypes, and 
different mutations can produce similar phenotypes. 
Variations in the percentage of mutant mtDNAs between 
patients must change the ATP output and cause the 
variation in clinical symptoms. Hence patients are generally 
classified by genetic defect rather than by clinical 
manifestation (5). However, the most common pathologies 
associated with mitochondria are not hereditary but 
associated with age and with the physiological or 
pathological production of mitochondrial ROS. 
 
Major pathologies for which it the role played by 
mitochondrial dysfunction and ROS production has been 
clearly established include all the common 
neurodegenerative diseases (Parkinson´s disease, 
Alzheimer´s disease, Huntington´s disease, epileptic 
seizures, FRDA), atherosclerosis, diabetes, ischemia-
reperfusion injury, cancer and aging. 
 
Therefore, the knowledge of the causes that result 
in an excessive production of mitochondrial ROS and/or 
the failure of its detoxification systems are necessary for 
the development of new therapeutic strategies. In order to 
understand the pathologies associated with mitochondrial 
dysfunction, one of the fundamental milestones is to 
underscore the differences in the susceptibility of different 
cell types to mitochondrial oxidative stress. The factors 
responsible for this variability include the inner 
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mitochondrial membrane lipid composition and /or the 
oxidant/antioxidant balance, (i.e. superoxide dismutase) 
and/or heat shock protein activity and expression as well as 
the glutathione status. It is also important to point out that 
most of these pathologies involve tissues with high 
metabolic rates and mitochondrial content. 
 
3. MITOCHONDRIAL OXIDATIVE STRESS 
PROTECTION SYSTEM 
 
ROS include a family of chemically reactive 
molecules derived from O2. Some of these molecules are 
extremely reactive, such as HO., while some others are less 
reactive like O2- and H2O2. Intracellular free radicals (free, 
low molecular weight molecules with an unpaired electron, 
are often ROS and vice versa, and the two terms are 
commonly exchanged). Free radicals and ROS can readily 
react with most biomolecules, starting a chain reaction of 
free radical formation. In order to interrupt this chain 
reaction, a newly formed radical must either react with 
another free radical, with cancellation of the unpaired 
electrons, or react with a free radical scavenger, also known 
as a chain-breaker or primary antioxidant. 
 
3.1 Detoxification enzymes 
3.1.1. Mn-SOD 
Superoxide anion is generated from molecular O2 
by the addition of one electron. It is not highly reactive, and 
it lacks the ability to penetrate lipid membranes and is 
therefore enclosed in the compartment where it was 
produced. The formation of O2- takes place spontaneously, 
especially in the electron-rich aerobic environment in the 
vicinity of the inner mitochondrial membrane containing 
the respiratory chain. Although O2- is not an effective 
oxidant, it impairs mitochondrial function by oxidizing the 
Fe-S centers of various enzymes. In addition, O2- can react 
with NO to produce peroxynitrite, an extremely powerful 
oxidant. 
 
Two molecules of O2- rapidly dismutate to H2O2 
in the presence of the superoxide dismutase enzymes 
(SOD). Mn-SOD is the SOD isoform that localizes in the 
mitochondrial matrix. It is an essential protein (sod2 knock-
out mice die soon after birth) (7). Several lines of evidence 
support the idea that Mn-SOD has tumor suppressor 
activity. In general, reduced levels of Mn-SOD are 
observed in many types of human tumors, whereas 
overexpression of Mn-SOD suppresses tumorigenicity. 
Life-long reduction in Mn-SOD activity (in heterozygotic 
sod2 +/- mice) results in a much higher incidence of cancer 
(7). It has been postulated that Mn-SOD anti tumorigenic 
activity is a direct consequence of the relieved 
mitochondrial oxidative stress caused by O2-, however it 
must be taken into account that Mn-SOD generates H2O2 
and therefore can generate a different type of oxidative 
stress in the absence of the corresponding H2O2 scavengers. 
Nevertheless, Mn-SOD seems to behave mainly as an 
antioxidant in most biological settings. Evidence 
supporting an antioxidant role for Mn-SOD include studies 
with transgenic mice over-expressing Mn-SOD in various 
tissues, they show increased tolerance to several oxidative 
stress situations including ischemia-reperfusion injury (8), 
streptozotocin induced beta-cell injury (9), 6-
hydroxydropamine injury to dopaminergic neurons (10), 
and adriamycin and paraquat toxicity (11). Importantly, the 
sod2 gene is transcriptionaly up-regulated by oxidative 
stress.  
 
3.1.2. Catalase 
Hydrogen peroxide is not a free radical, but it is 
highly important much because it is an essential 
intermediate in the formation of more reactive ROS 
molecules, particularly of hydroxyl radical (HO.) via 
Fenton reaction with transition metals. It also has the ability 
to penetrate biological membranes, and therefore H2O2 
generated in the mitochondria can readily diffuse into the 
cytosol. Hydrogen peroxide is removed by at least three 
antioxidant enzyme systems, catalases, glutathione 
peroxidases and peroxiredoxins. 
 
Catalase is mainly located in peroxisomes, where 
it catalyzes the dismutation of H2O2 to H2O and O2. It is 
likely to be responsible at least in part of the clearance of 
the H2O2 that is produced in the mitochondria and leaks out 
into the cytoplasm. The oxidative stress protective role of 
catalase is well established. Deficiencies in catalase activity 
are associated with oxidative stress related pathologies, and 
increased oxidant sensitivity. Cancer cells typically show 
reduced catalase levels. Inherited deficiency in catalase is 
associated with diabetes mellitus, hypertension and altered 
lipid, carbohydrate and homocysteine metabolism (12). 
Mice lacking catalase have increased sensitivity to various 
oxidants (13). In contrast, increased catalase levels are 
generally protective. Transgenic mice over-expressing 
catalase in various tissues show increased tolerance to 
ischemia-reperfusion injury and oxidative stress inducing 
agents such as adriamycin, paraquat (14) and streptozotocin 
induced beta-cell injury (9). Apolipoprotein E deficient 
(ApoE-/-) mice that over-express catalase show reduced 
atherosclerosis plaque formation (15), probably because 
over-expression of catalase in vascular smooth muscle cells 
(VSMC) inhibits H2O2 induced cell proliferation (a process 
that takes place during plaque formation) (16). Most 
importantly targeting of catalase to mitochondria extended 
life span in mice by 20% (17).  
 
3.1.3. Peroxiredoxins 
It is a family of enzymes capable of directly 
reducing hydroperoxides (i.e. H2O2 and different alkyl 
hydroperoxides). In the mitochondria of mammalian cells 
there are at least two members, Prx3, and Prx5. Prx3 
contains a mitochondrial localization sequence, is found 
exclusively in the mitochondrion and uses mitochondrial 
thioredoxin-2 (Trx2) as the electron donor for its 
peroxidase activity (18). Prx3 is induced by oxidants in the 
vascular endothelial cell system and is thought to play a 
role in the antioxidant defense system and homeostasis 
within the mitochondria (19). Prx5 has three isoforms 
originated by alternative splicing, one is present in the 
mitochondria, another in the nucleus and the third in 
peroxisomes. mtPrx5 is comparatively poorly characterized 
than Prx3, however the information available so far point to 
a very similar role to that of Prx3. It uses Trx2 as electron 
donor (20-24). 
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Both Prx3 and Prx5 are over-expressed in 
different forms of cancer (25, 26), including the best 
characterized breast cancer (27, 28). This observation 
contrast with the above mentioned reduced activity of both 
Mn-SOD and catalase in human malignancies. It has been 
proposed that both Prx3 and Prx5 protect malignant cells 
from H2O2 toxicity. 
 
Whereas low levels of H2O2 are essential for 
cell growth, elevated levels of H2O2 are toxic to the cell 
and can lead to apoptosis. Human solid tumors 
frequently show regions of hypoxia, and suffer elevated 
levels of H2O2. This situation can explain why Prx 
over-expression can be beneficial to cancer cells. 
Elevated Prx3 levels help to scavenge the excess H2O2 
and protect cells from H2O2 induced apoptosis (29). 
Similarly Prx3 protects cells during hypoxia (30), a 
situation that induces the mitochondrial production of 
ROS by the disruption of oxidative phosphorylation 
(31).  
 
However, in physiological conditions, low 
levels of H2O2 are an important cell proliferation 
signal. In these conditions Prx3 inhibits the growth 
stimulatory effects of H2O2. This effect can be crucial 
in the cardiovascular system where metabolic 
dysfunction in the endothelium generates an oxidative 
stress situation that initiates atherosclerosis processes. 
In this scenario excessive production of H2O2 by 
stressed endothelial cells promotes proliferation of 
VSMC, a process that could be prevented by Prx3. 
 
3.1.4. Thioredoxin and thioredoxin reductase 
The thioredoxin system consists of the two 
antioxidant oxidoreductase enzymes thioredoxin (Trx) and 
thioredoxin reductase (TrxR). The latter catalyzes the 
reduction of the active site disulfide in Trx using NADPH2 
and, among other functions, reduced Trx is a general 
protein disulfide reductant, and a specific electron donor 
for many Prx. 
 
Trx2 is located in mitochondria (24). The Trx2 
system includes Prx3, Trx2 and TrxR2. Prx3 utilizes Trx2 
as electron donor, and TrxR2 uses NADPH2 to regenerate 
reduced Trx. All tree are ubiquitously expressed, but are 
found at the highest levels in metabolically active tissues, 
such as heart (32), brain and liver (33, 34). Yeast mutants 
of any of these three proteins support their role in the 
protection against oxidative stress (35). Trx2 over-
expression can protect cells from oxidant-induced apoptosis 
and increase the mitochondrial membrane potential (36, 
37). Trx2-/- mice show early embryonic lethality. The 
timing of embryonic lethality coincides with the 
maturation of the mitochondria, since they begin 
oxidative phosphorylation during that stage of 
embryogenesis (38). Conditional Trx2 deficient cells 
show that upon loss of Trx2 cells show and increased 
accumulation of ROS, decreased mitochondrial GSH 
levels and induction of apoptosis (39). Trx2 is up 
regulated by ROS (40-42), and this regulation could be 
involved in preconditioning-induced protection from 
cardiac and neuronal ischemia.  
TrxR reduces not only the disulfide in oxidized 
Trx, but also some other protein disulfides or a wide 
spectrum of oxidized low molecular weight compounds, 
playing an important role in the regeneration of 
antioxidants. TrxR2 is located in mitochondria (43, 44). 
Deletion of TrxR2 results in embryonic lethality at day 13. 
These embryos have hematopoiesis deficiencies and are 
severely anemic, show increased apoptosis in the liver, and 
reduced cardiomyocyte proliferation, the cultured fibroblast 
are extremely sensitive to oxygen radicals. In order to 
investigate the putative role of mitochondrial dysfunction 
in the embryonic lethality, TrxR2 was specifically ablated 
in mice heart. These mice die shortly after birth of fatal 
dilated cardiomyopathy, a condition observed in 
Friedreich´s ataxia and associated with mitochondrial 
oxidative stress (45). Over-expression of a dominant 
negative form of TrxR2 in HeLa cells results in a higher 
concentration of H2O2 (46), while over-expression of 
TrxR2 increases resistance to cytotoxicity induced by 
inhibition of the mitochondrial complex III.  
 
3.1.5. Glutathione peroxidase and other glutathione 
related systems 
The tri-peptide glutathione (g-glutamyl-cyteinyl-
glycine) is an endogenous antioxidant of great importance. 
GSH is required for the maintenance of the thiol redox 
status of the cell, protection against oxidative damage, 
detoxification of reactive metals and electrophiles, storage 
and transport of cysteine, DNA synthesis, cell cycle 
regulation and cell differentiation (47). The key functional 
element of glutathione is the cysteinyl moiety, which 
provides the reactive thiol group. ROS are reduced by GSH 
in the presence of GSH peroxidase (GPx). As a result GSH 
is oxidized to GSSG, which in turn is rapidly reduced back 
to GSH by GSSG reductase (GR) at the expense of 
NADPH. The redox cycle also aids in maintaining reduced 
protein and enzyme thiols. Without it, vulnerable cysteinyl 
residues of essential enzymes might remain oxidized, 
leading to changes in catalytic activity. Glutathione is also 
an excellent scavenger of lipid peroxidation products such 
as HNE and acrolein. Glutathione reacts with carbon atoms 
via nucleophilic attack on an electrophilic carbon, in a 
reaction catalyzed by glutathione S-tranferase. GSH also 
has a high affinity for metal ions, and acts as a reductant in 
redox reactions involving metals. It also forms stable 
complexes with metals (mercury, lead, etc) and products of 
lipid peroxidation that can then be eliminated from the 
body. 
 
Another class of proteins intimately related to 
GSH are the glutaredoxins (Grx) and glutaredoxin 
reductase (GrxR), with functions overlapping those of 
thioredoxin system, the major difference being that Grx can 
be reduced directly by GSH and is capable of reducing 
GSH mixed protein disulfides formed at oxidative stress. 
 
Mitochondria have a high concentration of 
glutathione that must be imported from the cytosol via an 
specific carrier because it lacks the enzymes required for 
glutathione synthesis. Ethanol intake reduces the activity of 
the carriers (dicarboxylate and 2-oxoglutarate) in hepatic 
cells, sensitizing hepatocytes to oxygen radicals (48), 
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mitochondrial GSH depletion by beta-amyloid is associated 
with Alzheimer’s disease (AD) (49, 50). Changes in redox 
balance in the mitochondria are directly associated with 
alterations in the GSH/GSS ratio, and the induction of 
mitochondria-mediated apoptosis (51).  
 
The mitochondrial Grx2a (52) can use both GSH 
and TrxR2 as electron donors. It has been shown to play a 
role in the protection of thiols of mitochondrial proteins 
from formation of disulfides when the redox balance is 
altered in oxidative stress situations (53), and could also 
help to prevent cardiolipin oxidation and the initiation of 
the mitochondrial apoptotic cascade induced by agents like 
doxorubicin and 2-deoxy-D-glucose (54). It has also been 
proposed to act as a mitochondrial redox sensor that is 
activated when the glutathione pool becomes oxidized. 
(55). The mitochondrial glutathione reductase (mtGrxR) in 
an splice variant isoform of the gene coding for the 
cytoplasmic enzyme (56). 
 
Phospholipids that are rich in unsaturated fatty 
acids, are particularly susceptible to ROS attack. The result 
is the formation of lipid hydroperoxides. This process is 
particularly relevant in mitochondria where the electron 
transfer chain produces O2- and H2O2 at the mitochondrial 
inner membrane (57). GPx1 is the major GPx isoform, and 
it is present in all tissues; 10% of GPx1 localizes to 
mitochondria (mtGPx1) where it has been considered the 
most important H2O2 metabolizing enzyme in 
mitochondria, a view that was recently challenged (58). 
GPx4 is also called PHGPx and has three isoforms 
originated by alternative splicing, one present in the 
mitochondria (L-form), where it markedly reduces the lipid 
hydroperoxides generated in biomembranes. GPx4 over-
expression effectively prevents apoptosis induced by 
different stimuli, including oxidized low density 
lipoproteins (oxLDL), and cholesterol hydroperoxide (both 
important risk factors in atherosclerosis). It protects the 
mitochondrial lipid cardiolipin from oxidation and hence 
prevents the release of cytochome c from the mitochondrial 
inner membrane. It also prevents the inactivation of the 
adenine nucleotide transporter that leads to the opening of 
the membrane transition pore (MTP), exit of cytochrome c 
and initiation of apoptosis (59-62). GPx4 also reduces the 
accumulation of mitochondrial H2O2 in cells treated with 
agents that generate mitochondrial stress. It has been 
proposed that Gpx4 is important for the protection of the 
damage associated with ischemia-reperfusion injury (63). 
 
3.2 Other protection systems 
3.2.1. UCP-2 
It is a gated proton channel located in the 
mitochondria inner membrane, it decreases metabolic 
efficiency by dissociating substrate oxidation in the 
mitochondria from ATP synthesis.(64). Therefore, it can 
reduce the inner mitochondria membrane potential (delta-
Psi), reduce ATP synthesis, dissipate energy in the form of 
heat, and diminish the production of O2-. It was initially 
proposed to play a role in adaptive thermogenesis, however 
accumulated data support the notion that UCP-2 prevents 
the excessive production of O2- in mitochondria. In fact, O2-
has been shown to induce the expression of UCP-2 (65). It 
is also directly induced by H2O2 and under pathological 
conditions where excessive ROS production occurs (66-
69). However, the transcriptional regulatory mechanisms 
are not fully elucidated, its expression is induced by 
PPARalpha, and PGC-1alpha and it seems that activation 
requires high glucose and FFA, a putative protective 
mechanism since both are likely to increase ROS 
production. UCP-2-/- animals show increased free radical 
production in monocytes (70), UCP-2 deficiency in bone 
marrow precursors results in a significant increase in 
atherosclerotic plaque formation in mice (71). Its over-
expression has been proposed to be protective from ROS in 
various cell types and tissues. Cells that over-express UCP-
2 are more resistant to H2O2 treatments (72-74). UCP-2 
over-expression also reduces lipid peroxidation at least in 
the brain (75), where it protects neurons against seizure and 
neuronal damage (76, 77). Over-expression in 
dopaminergic neurons protects from Parkinson-inducing 
agents (78). Furthermore, increased expression of human 
UCP-2 in the adult fly nervous system extends fly life span 
(77). Importantly, UCP-2 has also been proposed to control 
glucose dependent insulin secretion in beta-cells, through 
the reduction of ATP synthesis, and concomitantly has 
been proposed to play a role in the pathogenesis of diet-
related type 2 diabetes.  
 
3.2.2. Heat shock proteins (HSP) 
In mammalian cells HSP synthesis is induced not 
only after hyperthermia, but also following a wide variety 
of stress conditions including oxidative stress (79), in fact it 
constitutes a fundamental mechanism necessary for cell 
survival under a wide array of toxic conditions that include 
mitochondrial oxidative stress (80). The induction of the 
heat shock response requires the activation and 
translocation to the nucleus of one or more heat shock 
transcription factors which control the expression of a set 
of protective heat shock proteins (81). The transcription 
factor HSF plays a crucial role in the transcriptional 
induction of HSP in stress conditions (82-84). Some of the 
best known HSPs include ubiquitin, Hsp10, Hsp27, Hsp32 
(HO-1), Hsp47, Hsp60, Hsc70, Hsp70 (Hsp72), Hsp90 and 
Hsp100/105 (85). The important and well-characterized 
Hsp70 family includes Hsc70, Hsp70, and GRP75. They 
are protein chaperones, that bind to unfolded proteins and 
return them to their native conformation trough an ATP 
dependent mechanism. Ubiquitin targets proteins to be 
degraded by the proteosome (86). 
 
Mitochondrial oxidative stress has been shown to 
induce a heat shock response (87). Several HSP have been 
found in the mitochondria where they could play a 
protective role. Hsp60 directs the entry of proteins into the 
mitochondria (88), its yeast homologue has been proposed 
to protect from oxidative stress (89). Glucose-regulated 
protein 75 (GRP75) (90), prevents the accumulation of 
ROS in mitochondria (91). Hsp10 exerts its chaperone 
function with proteins within mitochondria (92). Hsp10 is 
required for the folding and assembly of proteins imported 
into the matrix compartment, and is involved in the sorting 
of certain proteins, such as the Rieske Fe/S protein, passing 
through the matrix en route to the intermembrane space. 
Both Hsp10 and Hsp60 have been shown to protect 
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mitochondrial function in ischemia-reperfusion (93). Hsp70 
(Ssc1) regulates the entry and adequate folding in the 
mitochondria of proteins with Fe-S centers (94, 95) and is 
activated by Hsp40.  
 
Hsp32 has three isoforms, HO-1, HO-2 and HO-
3. HO-1 is the rate limiting enzyme in the production of 
bilirubin, a potent antioxidant. It catalyzes the specific 
oxidative cleavage of the heme molecule to form equimolar 
amounts of biliverdin and carbon monoxide (CO). HO-1 is 
rapidly up-regulated by oxidative and nitrosative stresses, 
as well as by glutathione depletion. Its promoter has an 
antioxidant responsive element (ARE) similar to other 
antioxidant enzymes (96). 
 
4. TRANSCRIPTION FACTORS 
 
All the above mentioned antioxidant defenses are 
induced by different stimuli in response to stress situations. 
Several transcriptions factors have been proposed to be 
activated in response to oxidative stress and/or modulate 
the expression of one or more protection genes. However 
until recently a specific and coordinated regulation of the 
mitochondrial system had not been described. The 
transcriptional coactivator PGC-1alpha has been shown to 
play that role and to be directly regulated by the 
intracellular levels of NO. The activity of the transcription 
factors is also tightly controlled by the cellular redox state 
as evidenced by the protein Raf-1 that is necessary to keep 
several transcription factors in a reduced/active 
conformation (97). 
 
4.1. Nrf1 and Nrf2 
Basal and inducible expression of a number of 
antioxidant defense genes are in part regulated by a cis-
acting DNA element known as the antioxidant responsive 
element, ARE, (98) that should be more properly called 
electrophyl response element, since it is present in genes 
that detoxify carcinogens, suggesting that induction trough 
ARE is chemopreventive, and not closely related to 
mitochondrial processes (99). However, activation through 
ARE appears to be driven by conditions that promote 
intracellular oxidative stress and therefore must be taken 
into consideration. A number of transcription factors have 
been proposed to bind to ARE, but the most recent studies 
point to the CNC subfamily of bZIP proteins as mediators 
of ARE function (100). They appear to function as obligate 
hererodimers with other bZIP proteins. 
 
Forced expression experiments of the bZIP 
proteins Nrf1 and Nrf2 suggest that they mediate ARE 
function (101). Nrf1-/- mice show embryonic lethality but 
Nrf1 null cells have been isolated and shown to have an 
increased sensitivity to the toxic effects of oxidants than 
their wild type controls (102). Nrf2-/- mice are viable but 
they show diminished expression of several phase 2 
enzymes (detoxification of xenobiotics) and are sensitive to 
treatments that cause oxidative stress (103, 104). The 
analysis of double knock-out animals shows they have 
overlapping functions and are functionally redundant in 
mediation ARE function and oxidative stress defense (105). 
The mechanism of signal transduction from xenobiotics to 
Nrf1 and Nrf2 has not been elucidated although it has been 
proposed to involve the activation and phosphorylation by 
PKC (106). 
 
4.2. AP-1 
The immediate early response expression of Jun 
and Fos (AP-1) controls the expression of many genes, and 
plays a central role in the control of cell proliferation and 
transformation. Among other stimuli, it is rapidly induced 
by H2O2, UV-C, UV-A, ionizing radiation etc. Its DNA 
binding activity is also induced by UV and H2O2 (99). 
Several signal transduction pathways and the direct action 
of oxidants on the proteins have been proposed to mediate 
their induction and activation. AP-1 has been shown to 
induce the expression of Mn-SOD (107), but the biological 
role of this regulation seems to be mainly related to the role 
played by Mn-SOD in tumor suppression (108, 109), and 
although it is possible that it is also relevant in the control 
of the celullar redox state, to date this possibility has not 
yet been tested. 
 
4.3. NFkappaB 
Nuclear factor kappa B (NFkappaB) plays a 
central role in the regulation of many genes involved in 
cellular defense mechanisms, apoptosis, pathogen defenses, 
immunological responses and expression of cytokines and 
cell adhesion molecules. ROS, generated in the 
mitochondria, have been proposed as the intermediate 
second messengers to the activation of NFkappaB by tumor 
necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1). 
NFkappaB activation can in fact be directly mediated by 
H2O2 and hydroperoxides (99). NFkappaB has been shown 
to induce Mn-SOD (110, 111), the biological role of this 
induction is not completely understood but it might be 
related with the induction of pro-survival signals in 
inflammatory situations where high levels of ROS are 
generally produced (112-114). 
It is a well-established fact that females live 
longer than males. Mitochondria from females produce less 
H2O2 and have higher levels of Mn-SOD and GPx. 
Estrogen is responsible for these differences. Interestingly, 
its effects do not seem to be mediated by the nuclear 
receptor ER, but by its interaction with a membrane 
receptor that signals to exert NFkappaB activation (115). 
 
4.4. HIF-1 
Hypoxia-inducible factor-1 (HIF-1) is a 
transcription factor that governs cellular responses to 
reduced O2 availability, a situation that is also prone to 
production of mitochondrial ROS. Upon O2 deprivation the 
degradation rate of the HIF-1 alpha subunit turn-over is 
reduced and the protein stabilized. Importantly it has been 
recently shown that HIF-1 stabilization requires 
mitochondrial ROS and is inhibited in the presence of high 
levels of GPx or catalase (116, 117). HIF-1 has also been 
proposed to up-regulate the Mn-SOD promoter although 
the biological significance of this regulation has not been 
established (118). 
 
4.5. PPARs 
The connection between peroxisome proliferator 
activated receptors (PPARs) and oxidative stress is still a
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Figure 2. High glucose increases mitochondrial ROS 
production leading to oxidative stress and endothelial 
dysfunction. PGC-1alpha induction activates mitochondrial 
function and increases its ROS detoxification capacity. 
Over-expression of PGC-1alpha in high glucose conditions 
prevents oxidative stress and endothelial dysfunction. 
 
non solved issue. PPARalpha has been shown to induce 
ROS production in liver where it can result in increased 
carcinogenesis risk (119). However several reports also 
point to PPARs as involved in the regulation of the 
inflammatory response, and possibly in the control of ROS 
production (120). Reports suggesting that PPARs can 
induce UCP-2 promoter are also suggestive of the 
involvement of PPARs in the control of cellular ROS 
production (121, 122). 
 
4.6. Foxo3a 
Foxo3a is the DNA binding transcription factor 
that up to date has been more clearly and directly involved 
in the protection against mitochondrial oxidative stress. 
Foxo3a is the human homolog of Daf-16 from C. Elegans, 
genetic data in C. elegans show that Daf-16 increases life 
span in response to reduced insulin/IGF-1 signaling (123), 
and has also been shown to modulate, metabolism and 
fertility in the worm. Foxo3a can protect from H2O2 
toxicity by directly inducing Mn-SOD and calalase genes 
(124). Regulation by insulin/IGF-1 activates protein kinase 
B (AKT) that phosphorylates Foxo3a and directs its 
exclusion from the nucleus (125). Therefore, Foxo3a is 
inactivated in high insulin (high glucose) conditions where 
lipid metabolism and mitochondrial activity are low. 
Foxo3a is also sensitive to redox status through its 
interaction with p66shcA (126). ERK directly 
phosphorylates p66shcA. In response to H2O2, inhibition of 
ERK activation represses p66shcA-dependent 
phosphorylation of Foxo3a, and facilitates Foxo3a entry 
into the nucleus (127). Importantly Foxo3a is also able to 
induce cell cycle arrest in stress conditions supporting the 
role of Foxo3a in cell survival under stress conditions. 
 
4.7. PGC-1alpha 
The discovery that caloric restriction is associated 
with increased longevity, was the first indicator of the 
important connection between the regulation of oxidative 
metabolism or in other words, mitochondrial function and 
the oxidative stress protection systems. The idea is at first 
sight paradoxical, since increased mitochondrial activity 
should be associated with an elevated production of ROS in 
the mitochondria, however, cells that are more dependent 
on oxidative phosphorylation than on glycolysis, were more 
protected against oxidative stress, had lower ROS levels 
and hence aged more slowly. The clue to this apparent 
paradox is very likely that the activation of oxidative 
metabolism and the mitochondrial function goes hand in 
hand with the induction of the ROS protection system. The 
transcription factor responsible for this coordinated 
regulation is PGC-1alpha. PGC-1alpha was originally 
characterized as an inducer of mitochondrial proliferation 
(128), it was later found to be also and activator of lipid 
catabolism (129) and liver gluconeogenesis (130).  
 
Two important characteristics of PGC-1alpha are 
its tissue-specific expression pattern and its inducibility by 
particular signals (131, 132). PGC-1alpha is selectively 
expressed in tissues that have high energy demands and are 
rich in mitochondria, such as heart, skeletal muscle, brown 
adipose, kidney, liver and brain (128, 130, 133, 134). Its 
activity and expression levels are induced by cold 
exposure, fasting and, exercise (133, 135, 136). Signaling 
pathways associated with these stimuli (p38 MAP kinase, 
beta-adrenergic/cAMP, nitric oxide, AMP kinase and Ca2+-
calmodulin kinase) activate PGC-1alpha and its 
downstream target genes by increasing PGC-1alpha 
expression or transactivation function (137-140). Previous 
studies using gain-of-function strategies (adenoviral-
mediated or transgenic expression of PGC-1alpha in 
cultured cells and in vivo) have demonstrated that the 
transcriptional coactivator PGC-1alpha promotes the 
activation of mitochondrial biogenesis and increases 
cellular respiration (128, 135, 141).  
 
On the other hand, studies in PGC-1alpha 
deficient mice have demonstrated the critical role for PGC-
1alpha in the control of cellular energy metabolism. 
Oxidative metabolism and mitochondrial function are 
impaired in several tissues in mice lacking PGC-1alpha, 
fewer and smaller mitochondria were found in slow twitch 
muscles. Accordingly, a reduction in the expression of 
nuclear genes encoding proteins involved in mitochondrial 
electron transfer chain (cytochrome c and cytochrome 
oxidase), the beta subunit of ATP synthase, as well as a 
reduction of the expression of Tfam A (that directs the 
replication of the mitochondrial DNA) were found in 
knockout PGC-1alpha animals (142, 143). 
 
Our group has recently proposed that PGC-1alpha 
coordinately regulates several key genes involved in the 
protection against mitochondrial oxidative stress, Mn-SOD, 
catalase, UCP-2, Prx3, Prx5, Trx2 y TrxR2 (Figure 2). 
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Cells that over-express PGC-1alpha produce less ROS and 
are protected against oxidative stress agents like high 
glucose and H2O2 (144).  
 
5. NITRIC OXIDE 
 
NO is a diatomic free radical which is a gas at 
room temperature, making it highly diffusible within the 
cell. Its major target is the soluble guanylate cyclase (sGC), 
an enzyme whose activation increases the concentration of 
cGMP, and the activation of the cGMP dependent kinase G 
(PKG). NO/cGMP/PKG signaling pathway was originally 
identified as playing a key role in blood pressure regulation 
promoting smooth muscle relaxation, (145). It was later 
found to play other important roles in endothelial 
physiology and maintenance, as well as in regulation of 
platelet aggregation, and peripheral and central 
neurotransmission (146). More recently it has been 
proposed to control mitochondrial number (147, 148). 
 
NO is produced from arginine and O2 through a 
reaction catalyzed by nitric oxide synthases (NOS). 
Traditionally, three types of NOS have been described: 
iNOS (inducible), nNOS (neuronal) and eNOS 
(endothelial). It has also been proposed the existence of a 
mitochondrial NOS (mtNOS), that is not encoded by an 
independent gene but could be an alternative spliced 
product or specifically modified version of one or more of 
the classical enzymes (149). This hypothesis is intriguing 
since NO has multiple targets within the organelle. 
Although the existence of mtNOS is still under debate there 
are interesting findings. First of all, it seems that eNOS is 
attached to the outer mitochondrial membrane, which 
indicates that mitochondria may regulates NOS activity and 
conversely, eNOS may regulate mitochondrial respiration. 
The idea that mitochondria themselves are capable of 
producing NO is an important concept in several 
physiological and pathological mechanisms. Although 
mitochondria are not expected to release physiological 
relevant levels of NO, NO readily reacts with O2- to 
produce peroxynitrite a highly reactive compound with 
important biological activities (150). 
 
A large body of evidence suggest that NO plays a 
dual role acting both as a pro-oxidant and as antioxidant in 
different biological settings. Most evidence points to 
peroxynitrite as the mayor mediator of NO prooxidant 
effects while how NO mediates its antioxidant effects has 
been a serious matter of controversy, although most 
evidence points to a putative role played by the 
mitochondria. We have recently shown that NO can 
modulate PGC-1alpha expression both positively and 
negatively and hence regulate the expression levels of the 
mitochondrial detoxification system (our unpublished 
results). Both the prooxidant and antioxidant effects of NO 
have been shown to be highly relevant in pathologies such 
as atherosclerosis, neurodenenerative diseases, and 
ischemia reperfusion. The dual effects of NO depend on 
one hand on the levels of NO, since low levels tend to be 
protective, while high concentrations are normally toxic to 
the cells. On the other hand, NO has direct effects (those 
that are direct consequence of its chemistry) and the most 
important, indirect effects (those mediated by the activation 
of the sGC/PKG pathway). 
 
5.1. Direct effects 
One of the most significant biological reactions 
of NO is with transition metals like Fe resulting in NO-
metal complexes. NO can react with heme iron containing 
proteins, a reaction that is highly reversible, or with non 
heme iron, a situation that results in the permanent 
inactivation of the target enzyme. Putative heme protein 
targets for NO include catalase, cytochrome oxidase (151), 
hemoglobin and peroxidase. NO reaction with non-heme 
iron, such as iron-sulfur clusters has been described with 
enzymes like NADH-ubiquinone oxidoreductase, cis-
aconitase and NADH: succinate oxidoreductase. However 
the biological relevance of these reactions is still to be 
determined, particularly for the non-heme reactions with 
low Km that depend on extremely high NO concentrations. 
 
Nitric oxide affects the mitochondrial respiratory 
chain through: a) inhibition of the cytochrome oxidase 
activity, b) inhibition of the electron transfer between 
cytochromes b and c and c) inhibition of NADH-
dehydrogenase activity (152). 
 
Inhibition of cytochrome oxidase activity. 
Cytochrome oxidase or complex IV is the terminal enzyme 
of the mitochondrial respiratory chain that is responsible 
for over 95% of cellular O2 consumption in mammals and 
that is inhibitable by NO in a direct interaction with the 
enzyme (153, 154). The inhibition takes place as NO 
competes with O2 for the binding site of the enzyme at the 
reactive center, increasing the operative Km of O2 for the 
enzyme. A consequence of cytochrome oxidase inhibition 
is a reduction of the capacity to use O2 in cells, a 
phenomenon known as ‘metabolic hypoxia’ (155). 
Inhibition of mitochondrial respiration occurs in a 
reversible and, concentration-dependent manner (151, 156). 
The degree of inhibition of cytochrome oxidase activity by 
NO depends on the O2 concentration in the reaction 
medium (152). The function of the interaction of NO with 
cytochrome oxidase is still a matter of controversy. Brown 
(153) proposed that NO inhibition of cytochrome oxidase 
might be involved in the physiological regulation of O2 
consumption rate. Shiva (157) has hypothesized that NO 
through the inhibition of complex IV increases the 
production of O2- by the electron transfer chain and the 
formation of H2O2. This increased ROS production can 
damage cellular systems (158), a phenomenon proposed as 
to take place in inflammatory conditions or in 
neurodegenerative diseases. Taking into account the 
affinity (association constant, Ka = 1-10 pM) of the 
reaction of NO with cytochrome oxidase, which is similar 
to the one for the NO interaction with sGC, it follows that 
both NO-heme interaction are likely to occur under 
physiological conditions.  
 
Inhibition of electron transfer between 
cytochromes b and c. The inhibition of electron transfer in 
ubiquinol-cytochrome c reductase (complex III) by NO 
results in an increased rate of O2- production in 
submitochondrial particles and in an increased rate of H2O2 
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production in whole mitochondria. The phenomenon is 
reversible and is not affected by the O2/NO ratio (152). 
 
Inhibition of NADH-dehydrogenase activity. 
Nitric oxide inhibits the mitochondrial respiration chain at 
this level through secondary mediators, likely through 
peroxinitrite (ONOO-) (159). The process results in the 
inhibition of the electron transfer activity of NADH-
ubiquinone reductase (complex I), and of related activities, 
such as malate-glutamate dependent mitochondrial 
respiration or NADH-cytochrome c reductase activity. This 
phenomenon takes place after relatively prolonged 
exposure of cells to NO and in conditions of reduced 
glutathione levels (152). 
 
5.2. Indirect effects 
Several observations support the notion that NO 
antioxidant properties are not restricted to the direct action 
of NO but are likely to be largely dependent on changes in 
gene expression and/or protein activity elicited indirectly 
by NO. Indeed, the induction of eNOS expression by H2O2 
(160) has been suggested to protect trained muscles from 
oxidative stress (161). Similarly, NO preconditioning 
prevents oxidative damage after myocardial infarction 
(162). These data suggest that a relatively limited ROS 
production is necessary to induce eNOS and the ROS 
detoxification systems. 
 
It has been proposed that NO acts as a positive 
regulator for cells and tissue metabolism. Long-term 
exposure of cells to NO induces mitochondrial biogenesis. 
This process involves increased expression of PGC-1alpha, 
nuclear respiratory factor 1 (NRF-1) and mitochondrial 
transcription factor A (Tfam A) (147, 148). 
 
Experiments from our laboratory have shown that 
PGC-1alpha over-expression not only promotes 
mitochondrial activity but also results in the induction of 
genes involved in mitochondrial oxidative stress protection. 
In turn, this results in reduced levels of ROS production in 
cells that express PGC-1alpha (144). These results led 
us to investigate if NO could regulate the mitochondrial 
oxidative protection system through the regulation of 
PGC-1alpha expression. We found that endothelial cells 
treated with NO donors showed an up-regulation in the 
mRNA levels of PGC-1alpha and its target genes, 
including the mitochondrial ROS protection system, and 
this regulation was directly mediated by PGC-1alpha. 
Moreover, analysis of tissues from eNOS-/- mice 
showed reduced levels of PGC-1alpha and the 
mitochondrial ROS protection system, supporting the 
physiological relevance of the regulation (our 
unpublished results). 
 
6. PATHOLOGIES 
 
6.1. Neurodegenerative diseases 
There is significant evidence that the 
pathogenesis of several neurodegenerative diseases, 
including Parkinson’s disease, Alzheimer’s disease, 
Friedreich’s ataxia (FRDA), epileptic seizures, multiple 
sclerosis and amyotrophic lateral sclerosis, may involve the 
generation of reactive oxygen species (ROS) and/or 
reactive nitrogen species (RNS) associated with 
mitochondrial dysfunction. The mitochondrial genome 
may play an essential role in the pathogenesis of these 
diseases, and evidence of mitochondria as a site of 
damage in neurodegenerative disorders is based in part 
on observed decreases in the respiratory chain complex 
activities in Parkinson’s, Alzheimer’s, and Huntington’s 
diseases. Such defects in respiratory complex activities, 
possibly associated with oxidant/antioxidant imbalance, 
are thought to underlie defects in energy metabolism 
and induce cellular degeneration. 
 
Several factors have been suggested to explain 
the exacerbated sensitivity to mitochondrial dysfunction 
of the central nervous system (CNS). The CNS has a 
large potential oxidative capacity due to the high level 
of tissue O2 consumption. However, the ability of brain 
to withstand oxidative stress is limited because of: a 
high content of easily oxidizable substrates, such as 
polyunsaturated fatty acids and catecholamines, a 
relatively low levels of antioxidants and antioxidant 
enzymes, the endogenous generation of ROS in specific 
reactions, the elevated content of iron in specific areas 
of the human brain (such as globus pallidus and 
substantia nigra) on top of the very little iron-binding 
capacity of the cerebrospinal fluid (low content of 
transferin). Moreover, the CNS contains non-replicating 
neuronal cells which, once damaged, may be 
permanently dysfunctional or committed to apoptosis 
(163). 
It is tempting to speculate that biochemical 
reactions based on free radical and reactive oxygen species 
play the pathogenetic role in all these neurodegenerative 
conditions, though it is yet undetermined what types of 
oxidative damage occur early in pathogenesis, and what 
types are secondary manifestations of the dying neurons. 
Delineation of the profile of oxidative damage in each 
disease will provide clues as to how the specific neuronal 
populations are differentially affected by individual disease 
conditions (164). 
 
6.1.1. Parkinson’s disease 
Parkinson’s disease is the second most prevalent 
neurological disorder, its major clinical manifestation are 
tremors in rest, bradykinesia, stiffness, and postural 
instability. Most patients also suffer cognitive problems. 
Pathologically it is characterized by the degeneration of the 
dopaminergic neurons located in the substantia nigra pars 
compacta, and the presence in the affected neurons of 
intracellular inclusions known as Lewy’s bodies, which are 
made up of insoluble tangles of the protein alpha-synuclein. 
Although the symptomatic treatment has progressively 
improved in the last years, at present it is not possible to 
slow down or prevent the death of the dopaminergic 
neurons (165). 
 
The etiology of the disease is still unknown, but 
accumulated evidence, both clinical and experimental, 
points out to the involvement of mitochondrial dysfunction 
and of oxidative stress. Mitochondria isolated from patients 
with Parkinson’s disease shows a reduced activity in 
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complex I (NADH-ubiquinone reductase) and increased 
production of ROS. Decreased complex I activity was 
observed in the substantia nigra of postmortem samples 
obtained from patients with Parkinson’s disease (166). 
These observations suggest that these alterations precede 
the clinical manifestations (167). 
 
Exposure to environmental toxins that in vitro 
inhibit mitochondrial complex I activity, such as paraquat, 
MPTP and rotenone, have been associated with an 
increased risk to develop Parkinson’s disease and have 
been used to establish animal models of the disease. 
Accordingly, dopaminergic neurons treated in vitro with 
complex I inhibitors show a reduction in electron transfer 
rates, lowered ATP levels and increased ROS production 
(168, 169). 
 
The excessive ROS production has multiple 
effects that eventually result in cell death. Mitochondrial 
ROS hampers the process of synthesis and accumulation of 
dopamine in dopaminergic vesicles. As a consequence 
there is an accumulation of free 6-hidroxydopamine (6-
HD), which behaves as a redox-cycling quinone in the 
presence of transition metals like Fe or Mn. This process 
serves to further exacerbate the production of ROS, and 
reduces the levels of dopamine. The neuron metabolism 
becomes glycolytic to compensate the mitochondrial 
defect, but excessive ROS finally block the glycolytic 
metabolism and result in apoptotic cell death. Increased 
lipid peroxidation is also observed, along with reduced 
glutathione levels, inhibition of the proteasome, and 
mutations in mtDNA, and at late stages in nDNA, The 
latter described effect seems to be responsible for the 
accumulation of alpha-synuclein in insoluble aggregates 
that are toxic to the cell. Neuronal cell death, and free 
dopamine activate the glia and initiate an inflammatory 
cascade that amplifies the damage (170-172). 
 
6.1.2. Huntington’s disease 
Huntington’s disease (HD) is an autosomal 
dominant neurodegenerative disorder caused by a 
pathological expansion of exonic CAG triplet repeats in the 
gene encoding the protein known as huntingtin (Htt) (173, 
174). Disease symptomatology and progression are due to 
massive neuronal dysfunction and death in the striatum and 
in the cerebral cortex later in the disease. There is 
significant evidence that energy production is impaired in 
HD (175). Panov (176) found that mitochondria isolated 
from patients with HD had lower membrane potential than 
mitochondria from control subjects and upon calcium 
addition they depolarized faster than controls. These 
defects precede by months the onset of pathological or 
behavioral abnormalities. Additional evidence of the role of 
mitochondrial dysfunction in the disease comes from the 
observation that treatment of rodents or primates with 3-
NP, an inhibitor of complex II and activator of the 
mitochondrial ATP-sensitive K channel (that regulates 
mitochondrial Ca2+ homeostasis) causes selective damage 
in the striatum that resembles the pathology and 
symptomatology of HD (177, 178). It seems that mutant 
Htt associates with mitochondrial membranes and 
somehow induces mitochondrial dysfunction trough the 
inhibition of succinate oxidation (179, 180). Mutant 
huntingtin causes decreased mitochondrial oxidative 
phosphorylation and ATP production (181) What is the 
molecular target, is still a matter of controversy. 
Apparently, mitochondrial dysfunction becomes relevant 
when glycolysis is inhibited, a process that has also been 
described in Parkinson’s disease patients (182), however it 
is not clear why glycolysis becomes deficient. Evidence for 
excessive ROS production and the role played by oxidative 
stress in the pathology is provided by the finding that the 
pathological deposits are immunoreactive to antibodies 
recognizing protein side-chains modified either directly by 
reactive oxygen or nitrogen species, or by products of lipid 
peroxidation or glycosylation. Although the source(s) of 
increased oxidative damage is not entirely clear, the 
findings of increased localization of redox-active transition 
metals in the brain regions most affected is consistent with 
their contribution to oxidative stress.  
 
6.1.3. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common 
form of dementia, and it is by definition characterized by 
the accumulation in the brain of extracellular neuritic 
plaques, together with the presence of intraneuronal 
neurofibrillary tangles (NFT) and progressive 
neurodegeneration. The plaques are composed of amyloid-
beta, a peptide derived from the precursor protein (APP) 
(183). 
 
Mitochondrial abnormalities, namely a decrease 
in mitochondrial mass and reduced mtDNA content, have 
been identified as a very early pathological sign in AD, 
preceding the appearance of NFT. The activity of key 
mitochondrial enzymes, mainly cytochrome oxidase is 
decreased in AD as well as mitochondrial membrane 
potential. Impaired complex IV activity has also been 
reported in Alzheimer’s disease (184). The suggestion has 
been that AD results from the accumulation of 
mitochondrial mutations affecting mainly the complex IV. 
It has been suspected for many years that the pathogenesis 
involves oxidative stress, and it has been proposed that 
mitochondrial dysfunction may be a primary disorder in 
AD patients. Crucial supporting evidence comes from 
experiments showing that mitochondria isolated from the 
platelets of AD patients and introduced into a rho0 neuronal 
cell line by cell fusion showed increased rates of ROS 
generation and disturbed Ca2+ balance compared to control 
cybrids.  
 
Significant increases in the levels of 
hemoxygenase-1 (HO-1) have been observed in AD brains 
in association with neurofibrillary tangles (185), and HO-1 
mRNA was found to be increased in AD neocortex and 
cerebral vessels (183). HO-1 increase was not only detected 
in association with neurofibrillary tangles, but also co-
localized with senile plaques and glial fibrillary acidic 
protein-positive astrocytes in AD brains (187). It has been 
proposed that the dramatic increase in HO-1 in AD may be 
a direct response to increased free heme associated with 
high levels of mitochondrial turnover. Removal of 
defective mitochondria would therefore induce HO-1 
expression as an attempt to convert the highly damaging 
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heme into the antioxidants biliverdin and bilirubin. This 
process could explain the high levels of free Fe and Cu 
found in affected neurons. As previously mentioned free 
Fe2+ and Cu2+ catalize the Fenton reaction that produces the 
highly reactive HO. from H2O2 (188). The resulting damage 
facilitates the formation of beta-amyloid deposits (189). 
 
Evidences for oxidative damage to proteins, DNA 
and increased lipid peroxidation have all been reported 
(190). Acrolein and HNE are increased in AD brain (191, 
192), and HNE is covalently bound in excess to the 
glutamate transporter in AD (190). The latter finding, that 
could also be induced by addition of beta-amyloid to 
synaptosomes, coupled with the reported loss of glutamine 
synthetase activity in AD brain (190), suggest that 
glutamate-stimulated excitotoxic mechanisms could be 
important in the neurodegeneration in AD. 
 
APP expression is induced in response to stress 
situations like hypoxia/ischemia. Therefore, it has been 
considered that APP could be a member of the cellular 
defense system to prevent neuronal death. However, 
accumulated beta-amyloid, forms Ca2+ channels that 
facilitate the massive entry of intracellular Ca2+ and the 
induction of apoptosis (194). Since the expression pattern 
of APP closely resembles that of heat shock proteins, HSPs 
have been intensely studied in brains of patients with 
Alzheimer’s disease (195-199). 
 
Local hypoxia due to vasculature malfunction and 
impaired microcirculation has been proposed as the origin 
of the mitochondrial dysfunction associated with advanced 
age. Risk factors like diabetes and hypercholesterolemia 
can induce mitochondrial dysfunction and oxidative stress 
in the vascular endothelial cells. The resulting endothelial 
degeneration would lead to a situation of local hypoxia or 
chronically impaired O2 delivery to brain areas that will 
lead to mitochondrial oxidative stress in the glia, neurons 
and astrocytes (200). 
 
6.1.4. Epilepsy 
Epilepsies are a group of clinical syndromes that 
affect more than 50 million people worldwide. Epileptic 
seizures can be convulsive or nonconvulsive episodes 
characterized by synchronized abnormal electrical activity 
arising from a group of cerebral neurons. In contrast with 
genetic forms of epilepsy, acquired epilepsy accounts for a 
approximately 60% of all cases and is usually preceded by 
injury such as an episode of prolonged seizures or status 
epilepticus, febrile seizures, hypoxia, or trauma (201). 
These initial insults are thought to set in motion complex 
changes that result over time in the development of 
spontaneous recurring seizures. Neuronal death is 
considered by most the propagating factor being both the 
cause and the consequence of epileptic seizures. This idea 
is supported by the fact that surgical removal of damaged 
hippocampus improves the condition of epilepsy patients 
(202). 
 
Evidence for mitochondrial dysfunction in 
epilepsy derives from the observed dramatic metabolic and 
bioenergetic changes that occur as consequence of both 
acute seizure episodes and chronic epilepsy. In acute 
seizures there is a huge increase in glucose uptake, and 
glycolysis. However, the mitochondrial utilization of 
pyruvate is not increased, resulting in lactate buildup (203). 
During interstitial phases (between seizure episodes), 
hypometabolism is prevalent and associated with a low 
mitochondrial activity (204). These evidences have 
provided a basis for the management of epilepsies that can 
be treated by caloric restriction and/or a ketogenic diet 
(205). A prominent support of the role played by 
mitochondrial dysfunction in epilepsy comes from the 
occurrence of familiar epilepsy due to mutations in mtDNA 
or mutations in nuclear genes that alter mitochondrial 
function. Well characterized examples include, myoclone 
epilepsy and ragged-red fiber disease (MERRF), due to a 
point mutation in mitochondrial tRNA Lys (206). 
 
Although a precise role for ROS in epilepsies 
remains to be defined, a general role for ROS in seizure-
induced neuronal death is supported by several 
observations: repeated seizures result in increased oxidation 
of cellular macromolecules, lipid peroxidation (207), and 
oxidative DNA damage (208). 
 
The mitochondrial origin of ROS has been 
demonstrated in rats. Kainate-induced seizures inactivate 
O2- sensitive mitochondrial aconitase but not the cytosolic 
isoform, indicating mitochondria as the major site of 
seizure induced O2- production The physiological relevance 
of mitochondrial ROS production is supported by the 
observation that in transgenic mice overexpressing Mn-
SOD both aconitase inactivation and neuronal loss are 
attenuated (209), while both are exacerbated in mice 
partially deficient in Mn-SOD (210, 211). Mitochondrial 
production of O2- during seizures has also been 
demonstrated in an epilepsy rat model that is induced by 
lithium/pilocarpine (212, 213).  Aconitase inactivation by 
O2- releases Fe2+ that reacts with H2O2 to produce OH- 
(211). 
 
A relevant role played by ROS in the disease has 
been demonstrated. Seizure-induced oxidative damage 
correlates with neuronal vulnerability, and oxidative 
damage occurs in areas that are vulnerable to kainate-
induced damage. Also indicative is the observed strong 
age-dependency associated with neuronal damage (211). 
On the other hand, high levels of UCP-2 expression protect 
from seizure-induced ROS production (214). The central 
role of mitochondria is also supported by the observed 
activation of the mitochondrial apoptotic pathway (215, 
216). 
 
6.1.5. Friedreich ataxia (FRDA) 
Friedreich ataxia (reviewed in (217)) is the 
commonest form of inherited ataxia. FRDA is an autosomal 
recessive degenerative disorder characterized by 
progressive gait and limb ataxia, loss of limb deep tendon 
reflexes, spasticity and extensor plantar responses (218). 
The causative mutation of FRDA is an abnormally 
expanded GAA triplet repeat in the first intron of the 
FRDA gene (219). Mutations in the FRDA gene, result in 
reduced expression of a protein called frataxin, which has 
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been shown to be localized in mitochondria (220). It is 
clearly established that frataxin in yeast plays an important 
role in the maintenance of mitochondrial iron homeostasis 
and cellular respiration. Deletion of the yeast frataxin 
homolog YFH1 results in a 10-fold increase in free iron 
within mitochondria along with increased ROS production, 
loss of mitochondrial DNA, and inability to carry out 
oxidative phosphorylation (221, 222). Further studies showed 
that frataxin deficiency leads to excessive free radical 
production in mitochondria and dysfunction of iron-sulfur 
cluster (ISC) containing enzymes (complexes I, II and III, and 
aconitase). Importantly, human frataxin complements YFH1, 
suggesting that frataxin function is conserved. 
 
Loss of mitochondrial function and impaired 
oxidative phosphorylation, with severe deficiencies of 
mitochondrial respiratory chain complexes I and II/III and 
aconitase activities, have been observed in post-mortem 
samples from FRDA patients, associated with reduced 
levels of mitochondrial DNA and with increased iron 
deposition. Aconitase deficiency is suggestive that 
oxidative stress may induce a self-amplifying cycle of 
oxidative damage associated with mitochondrial 
dysfunction, which may also contribute to cellular toxicity 
and degeneration (223). There are also evidences of an 
impairment in vivo of glutathione homeostasis and 
antioxidant enzymes in patients with Friedreich’s ataxia, 
suggesting a relevant role of free radical cytotoxicity in the 
pathophysiology of the disease. The precise sequence of 
events in FRDA is uncertain. However, impaired 
intramitochondrial metabolism associated, with increased 
free iron, and the consequent oxidative stress, are being 
considered as a possible pathogenic mechanism. Several 
model systems have been developed to understand the 
disease. Both decreased expression of frataxin protein 
(224), and selective inactivation in neuronal tissues are 
associated with neurological symptoms, mitochondrial 
iron-sulfur cluster-containing enzyme deficiencies and 
time-dependent mitochondrial iron accumulation (225).  
 
Although the precise function of frataxin remains 
unknown, there is evidence to suggest that frataxin acts as a 
chaperone for Fe2+ and a storage compartment for excess iron 
(226), Fe-S cluster assembly (227), and prevention of oxidative 
stress. It also might detoxify ROS via activation of glutathione 
peroxidase and elevation of thiols (228). An early step of ISC 
synthesis, which takes place on the scaffold protein Isu1, is 
greatly enhanced by frataxin. It has been proposed that frataxin 
directly binds iron, shielding it from H2O2 and making it 
available for ISC synthesis. It is unclear whether this 
postulated chaperone function is specific to ISC synthesis. 
Yeast data indicate that heme synthesis may also be stimulated 
by frataxin, suggesting a frataxin more general role in 
mitochondrial iron handling. Alternative hypotheses view 
frataxin as a stabilizer of a complex including Isu1 and the 
nascent ISC, as a protein with a primarily antioxidant function, 
and as an activator of the respiratory chain. 
 
6.2. Cancer and ageing 
6.2.1. Cancer 
Even though there is a large body of literature 
linking free radicals and antioxidant enzymes to cancer, 
most of the evidence is correlative, (i.e. cancer cells are 
nearly always low in Mn-SOD and catalase activity (229)). 
Evidence for a causal relationship is that in various model 
systems, ROS cause cancer (230). Moreover, antioxidants 
in general, and SOD and SOD-mimetics in particular, 
inhibit malignant transformation. Molecular biology 
techniques have been used to show a role for SOD in 
transformation. Over-expression of Mn-SOD by cDNA 
tranfection leads to inhibition of radiation-induced 
transformation in mouse fibroblasts (231), and over-
expression of Mn-SOD in several cancer cell lines led to 
suppression of cell growth. Mn-SOD in combination with 
chemicals that inhibit H2O2 removal causes cell killing of 
cancer cells by H2O2 toxicity. Moreover, Mn-SOD 
suppresses tumor metastasis (232). On the other hand, life-
long reduction in Mn-SOD activity (in heterozygotic sod2 
+/- mice) results in a much higher incidence of cancer (233),  
 
The origin of cancer is multifactorial, the best 
characterized carcinogens are those that damage DNA 
directly, followed by those that directly alter mitosis (i.e. 
those that modify the structure of microtubules). However, 
the relevance of carcinogens whose main action is the 
increased production of ROS, is becoming evident (234, 
235). ROS can mutate DNA both directly and indirectly. 
Free radicals, capable of both directly damaging DNA and 
affecting the DNA repair machinery, enhance genetic 
instability of affected cells, thus contributing to the first 
stage of neoplastic transformation also known as 
"initiation". The activation of pro-inflammatory factors like 
NFkappaB and AP-1 contribute to the setting of a oxidative 
stress situations, and deregulation of the machinery that 
controls cellular proliferation. In fact chronic inflammation 
has long been suggested to constitute a risk factor for a 
variety of epithelial cancers such as malignancies of 
prostate, cervix, esophagus, stomach, liver, colon, 
pancreas, and bladder. The inflammatory response is 
typically accompanied by an increased generation of 
free radicals and an increased production of cytokines, 
chemokines, growth factors and angiogenic factors. 
Cytokines and growth factors can further promote tumor 
growth by stimulating cell proliferation, adhesion, 
vascularization, and metastatic potential of later stage 
tumors. (236). ROS may have a multifactorial origin, 
mitochondria being one of the possible sources. Arsenic, 
a well characterized and common carcinogen, damages 
mitochondria and promotes mitochondrial ROS 
production (237, 238), and the carcinogen 
benzo(a)pyrene induces mitochondrial dysfunction 
(239). Importantly, the accumulation of mutations in 
people not exposed to carcinogens is associated with the 
presence of peroxidized lipids. Ultra sensitive methods 
for measuring DNA adducts allow the quantification and 
elucidation of DNA damage arising from oxidative 
stress and lipid peroxidation, which have been found to 
be the driving forces in several human malignancies. 
DNA damage in unexposed individuals has been shown 
unequivocally due to lipid peroxidation products (240). 
The accumulation of lipid peroxidation products is a 
normal consequence of mitochondrial dysfunction and 
ROS production in subjects with hyperlipidemia and/or 
hyperglycemia. 
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A number of studies have reported a high 
incidence of mtDNA mutations in cancer cells implicating 
these mutations in the process of carcinogenesis (241). 
Mitochondrial genomic aberrations have been reported in 
solid tumors of the breast, colon, stomach, liver, kidney, 
bladder, head/neck, and lung. Alterations in the expression 
of mtDNA transcripts in a variety of cancer types are also 
well described. In solid tumors, the observed elevated 
expression of mtDNA-genes coding for subunits of the 
mitochondrial electron respiratory chain may reflect 
mitochondrial adaptation to perturbations in cellular energy 
requirements (242). Mitochondrial DNA mutations can 
initiate a cascade of events leading to a continuous increase 
in the production of reactive oxygen species (persistent 
oxidative stress), a condition that probably favors tumor 
formation.  
 
In general, cancer cells show an elevated 
production of mitochondrial ROS and a low metabolic 
capacity (243), associated to an exacerbated sensibility to 
ROS and inhibitors of mitochondrial functions (244). 
Therefore, the generation of ROS could be exploited 
therapeutically in the treatment of cancer. One of the first 
developed drugs that generate ROS was procarbazine, that 
is readily oxidized to its azo derivative generating ROS. 
Forty years ago, Berneis reported a synergistic effect in 
DNA degradation when procarbazine was combined with 
radiation; this was confirmed in preclinical in vivo models. 
Early uncontrolled clinical trials suggested an enhancement 
of the radiation effect with procarbazine, but two 
randomized trials failed to confirm this. The role of ROS in 
cancer treatments and in the development of chemotherapy 
resistance is now better understood. The possibility of 
exploiting drugs that by redox cycling generate O2- and 
H2O2 or other ROS as cancer treatment is re-emerging as a 
promising therapeutic option with the development of 
agents such as buthionine sulfoximine and motexafin 
gadolinium (245). 
 
6.2.2. Aging 
Harman in 1972 first proposed that mitochondria 
may have a central role in the process of ageing. According 
to this theory, free radicals generated through 
mitochondrial metabolism can act as causative factor of 
abnormal function and cell death. Mitochondria are the 
cellular most significant source of oxidants and in vitro 
studies have indicated that approximately 1-2% of electron 
flow through the electron transfer chain results in the 
generation of O2-. Moreover, various toxins in the 
environment can injure mitochondrial enzymes, leading to 
increased generation of free radicals that over the lifespan 
would eventually play a role in aging (246, 247). 
 
Mitochondrial generation of ROS is a major 
cause of cellular damage that accumulates over time and 
seems responsible for aging (248). During aging some of 
the free radical scavenging systems are decreased (249, 
250) and as a consequence an increased escape of free 
radicals occurs, targeting lipids, proteins and DNA in 
proximity to the respiratory chain (251). Oxidized lipids 
decrease the fluidity and increase the permeability of the 
inner mitochondrial membrane (252). Oxidative damage 
proteins also increase markedly with age (249). Toxic roles for 
oxidized proteins have been proposed (i.e. Alzheimer’s 
disease). Furthermore, levels of the oxidized nucleotide 8-
hydroxy-deoxyguanosine (8-OH-dG), a biomarker of DNA 
damage has been show to increase in aging. In high metabolic 
tissues like brain and muscle, levels of 8-OH-dG in mtDNA 
exceed that of nuclear DNA nDNA some 16-fold (254). 
Finally, several age-related disorders (Parkinson, Alzheimer, 
etc.) have been shown to be linked to higher levels of mtDNA 
mutations than the age-matched controls (241, 255). 
 
The levels of cardiolipin, an acidic phospholipid 
that occurs only in mitochondrial inner membrane, decrease 
with age. Cardiolipin is involved in protein translocation 
and has electrical insulating properties, contributing to the 
maintenance of transmembrane potential (256). Typically, 
mitochondria from aged subjects have decreased membrane 
potential (257), reduced cytochrome c levels (258), and are 
larger and less numerous. They also show vacuolization, 
cristae rupture and accumulation of paracrystalline 
inclusions, indicating that mitochondrial function is 
severely impaired (259, 260). 
 
6.3. Diabetes, atherosclerosis and isquemia reperfusion 
injury 
6.3.1. Diabetes 
It is well established that mitochondrial function 
is required for normal glucose-stimulated insulin secretion 
from pancreatic beta cells. Several lines of evidence 
indicate that insulin resistance is an early feature of type 2 
diabetes. As skeletal muscle and liver become more and 
more insulin resistant, beta cell production of insulin 
increases. When type 2 diabetes develops beta cells do not 
secrete enough insulin to compensate for the increased 
demand.  
 
Beta cell dysfunction can be directly associated 
with a reduced mitochondrial function, as evidenced by the 
observation that increased UCP-2 levels that impair 
mitochondrial ATP synthesis also prevent insulin secretion 
(261). Both elevated glucose levels (262) and high 
concentration of triglycerides in plasma (263) that are 
important risk factors for type 2 diabetes have been proposed 
to be responsible for mitochondrial dysfunction, reduced ATP 
synthesis and elevated ROS levels in beta cells. A recent study 
demonstrates that hyperglycemia-induced mitochondrial O2- 
production activates uncoupling protein 2, which decreases the 
ATP/ADP ratio and thus reduces the insulin-secretory 
response. These data suggest that pharmacologic inhibition of 
mitochondrial O2- overproduction in beta cells exposed to 
hyperglycemia could prevent a positive feed-forward loop of 
glucotoxicity that drives impaired glucose tolerance toward 
frank type 2 diabetes (264). 
 
6.3.2. Atherosclerosis 
In atherothrombosis, ROS are responsible for the 
initiation and perpetuation of the pathological process. Each of 
the known risk factors for atherotrombosis promotes vascular 
oxidant stress, including hypercholesterolemia, hyperglicemia, 
hypertension, diabetes mellitus, tobacco use and 
hyperhomocysteinemia. Under normal circumstances, 
endothelial cells provide a permeability barrier to blood cells 
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and macromolecules, maintaining the relaxed state of the blood 
vessel, with limited affinity for circulating leucocytes, 
suppressing VSMC migration and maintaining a local 
antithrombotic environment. Upon exposure to risk factors, the 
phenotype of the endothelial cells changes. It becomes 
permeable to blood cells and macromolecules, is avid for 
leucocytes, promotes VSMC migration and proliferation and 
supports thrombotic responses. Endothelial dysfunction is 
associated with a loss of the normal bioactivity of NO. This 
decrease in NO bioactivity is a consequence of decreased 
production by eNOS, increased oxidative inactivation of NO 
by O2-, or both (265, 266). 
 
The initiation of the atherosclerosis processes is 
due in part to the deposition of oxidized lipids, like 
cholesterol, in the vascular wall. It seems that the clearance 
rate of oxidized cholesterol and other oxidized lipids is 
much slower than that of normal cholesterol. The oxidation 
of lipids takes place because of the excessive production of 
ROS in the endothelium. The initial endothelial dysfunction 
can be attributable to the mitochondrial production of ROS 
in the case of hyperglycemia, it has been shown that 
elevated glucose levels impair mitochondrial function and 
induce the production of mitochondrial ROS by complex II 
(267). 
 
6.3.3. Ischemia reperfusion injury  
Perhaps it seems self-evident that, if cells are 
deprived of glucose and oxygen, they will eventually die. 
In stroke and in cardiac infarct, this clearly defines cell 
death in the short term. However, there is a prevalent 
strange phenomenon, which is that cells that have been able 
to withstand a period of ischemia paradoxically die when 
they are reperfused. This has been called reperfusion injury 
or the oxygen paradox. Although the mechanism has not 
been fully elucidated, it seems likely that, as mitochondrial 
respiration is inhibited and ATP gradually falls, anaerobic 
glycolysis generates intracellular acidosis. The acidification 
drives the entry of Ca2+ into the cell. At reperfusion the 
mitochondrial potential abruptly recovers at a time when 
cytosolic Ca2+ is high, mitochondria will therefore become 
overloaded with Ca2+. Simultaneously, the abrupt return to 
respiration will be accompanied by a burst of mitochondrial 
free radical generation. The combination of high 
mitochondrial calcium and oxidative stress with low ATP 
levels and high Pi provides the setting for the opening of 
the permeability transition pore, collapse of membrane 
potential and induction of apoptosis (268, 269). 
 
7. CONCLUSIONS AND PERSPECTIVES 
 
Although it has long being established the 
fundamental role that mitochondria play to sustain aerobic 
life, it is but recently that it has emerged the notion that 
mitochondrial dysfunction is at the core of a vast array of 
major human pathologies. The final general conclusion is if 
anything surprisingly simple, sick mitochondria means sick 
bodies and the most affected tissues are those that either 
have high metabolic rates, like skeletal muscle, heart, and 
neurons, or are particularly sensitive to changing metabolic 
conditions such as beta-cells or vascular endothelial cells. 
But, why do mitochondria get sick? The answer is again 
appallingly self evident, it can be due to metabolic overload 
(high levels of glucose or lipids, metabolic syndrome), to 
the direct action of toxic chemicals on the mitochondria, 
like rotenone, or to mutations in certain genes. 
 
However, there is still a long way to go in order 
to understand how the mechanism that protect 
mitochondria from oxidative stress work and are regulated, 
and this knowledge is fundamental to be able to develop 
new therapies. Until then, the best way to go is to follow 
the advice of your physician, have a healthy diet and 
exercise regularly. 
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